Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3503 - Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): results from the FOXFIRE prospective randomized studies

Date

09 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Colon and Rectal Cancer

Presenters

Alastair Gray

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

A.M. Gray1, J. Wolstenholme2, F. Fusco2, I. Chau3, L. Dunham4, S. Love5, A. Roberts6, J. Moschandreas5, P. Virdee5, V. Lewington7, G. Wilson8, P. Tait9, N. Khan10, D. Berry11, A. Wotherspoon12, B. Morgan13, H. Wasan14, G. Van Hazel15, P. Gibbs16, R. Sharma17

Author affiliations

  • 1 Health Economics Research Centre, Nuffield Department Of Population Health, University of Oxford, OX3 7LF - Oxford/GB
  • 2 Nuffield Department Of Population Health, University of Oxford, OX3 7LF - Oxford/GB
  • 3 Oncology, Royal Marsden Hospital, London/GB
  • 4 Clinical Research, Oncology Clinical Trials Office, University of Oxford, Oxford/GB
  • 5 Centre For Statistics In Medicine, University of Oxford, Oxford/GB
  • 6 Addenbrooke’s Hospital, Cambridge Cancer Trials Centre, Cambridge/GB
  • 7 Nuclear Medicine Department, Guy's Hospital, King's College London, London/GB
  • 8 Oncology, The Christie NHS Foundation Trust, Manchester/GB
  • 9 Radiology, Imperial College Healthcare NHS Trust & Imperial College, London/GB
  • 10 Radiology, Royal Marsden and Chelsea & Westminster Hospital, London/GB
  • 11 Surgery, Cardiff and Vale University Health Board, Cardiff/GB
  • 12 Pathology, The Royal Marsden NHS Foundation Trust, London/GB
  • 13 Radiology, University of Leicester, Leicester/GB
  • 14 Oncology, Imperial College Healthcare NHS Trust & Imperial College, London/GB
  • 15 University Of Western Australia, University of Western Australia, Perth/AU
  • 16 Western Hospital, Western Hospital, Footscray/AU
  • 17 Ucl Cancer Institute, NIHR University College London Hospitals Biomedical Research Centre, London/GB
More

Resources

Abstract 3503

Background

Quality of life (QoL) in patients with colorectal cancer and liver metastases treated with selective internal radiotherapy (SIRT) using Yttrium-90 resin microspheres combined with FOLFOX (standard chemotherapy) has not been compared to FOLFOX alone. We report QoL results from a prospectively pooled analysis of 3 multicentre randomized trials: FOXFIRE, FOXFIRE-Global and SIRFLOX.

Methods

Patients were randomized to FOLFOX or FOLFOX+SIRT in 14 countries. Second-line therapy was permitted upon disease progression. EORTC QLQ-C30 and EuroQoL EQ-5D (3 level) questionnaires were given to all patients at baseline, 2-3, 6 and 12 months from starting treatment and yearly thereafter, and at disease progression. We compared QoL scores between arms at each timepoint, calculating mean differences adjusted for baseline scores, using a 5% significance level. No missing data imputation was performed.

Results

1103 patients were randomised overall. Questionnaire response rates ranged from 92% (1010/1103) at baseline to 33% (163/493) at 24 months. Patients randomised to SIRT showed significantly (p 

Conclusions

This analysis has shown that QoL is slightly impaired in functioning and symptom domains 4-8 weeks after treatment with SIRT+FOLFOX compared with FOLFOX alone, but slightly better when measured at disease progression. These differences were consistent between the QLQ-C30 and EQ-5D instruments. The differences detected were not large enough to be considered clinically significant.

Clinical trial identification

FOXFIRE ISRCTN83867919; SIRFLOX NCT00724503; FOXFIRE-Global NCT01721954

Legal entity responsible for the study

University of Oxford

Funding

Bobby Moore Fund of Cancer Research UK; Sirtex Medical Ltd

Disclosure

I. Chau: Advisory Board: Sanofi Oncology, Eli Lilly, Bristol-Myers Squibb, MSD, Bayer, Roche, Five Prime Therapeutics. Research funding: Janssen-Cilag, Sanofi Oncology, Merck Serono, Novartis. Honorarium: Taiho, Pfizer, Amgen, Eli Lilly, Gilead Science. S. Love: Grants from: Cancer Research UK, Sirtex Medical and non-financial support from Sirtex Medical. J. Moschandreas: Grants from Cancer Research UK, Sirtex Medical and non-financial support from Sirtex Medical. P. Virdee: Grants from Cancer Research UK, Sirtex Medical and non-financial support from Sirtex Medical. P. Tait: Medical advisor and medical proctor for Sirtex medical. H. Wasan: Grants, personal fees, non-financial support and other uncompensated work from Sirtex Medical. G. Van Hazel: Compensation for participation in advisory committees from Sirtex. P. Gibbs: Personal fees from Sirtex. R. Sharma: Research funding, honoraria and consultancy fees from Sirtex Medical. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.